CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $3.54B, above the global median of $1.2B
- FinancialsAltman Z-Score 9.95: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.54BUSDvs all stocks (USD)
Revenue (TTM)
606.33MUSDvs all stocks (USD)
Profit Margin
-7.66%vs Biotechnology peers
Beta
0.5410xvs all stocks
52-Week Change
29.77%vs all stocks
Market Capitalization
3.54BUSDvs all stocks (USD)
Enterprise Value
2.96BUSDvs all stocks (USD)
Forward P/E
31.33xvs Biotechnology peers
Price to Sales (TTM)
5.84xvs Biotechnology peers
Price to Book (MRQ)
9.45xvs Biotechnology peers
Enterprise to Revenue
4.88xvs Biotechnology peers
Enterprise to EBITDA
-64.09xvs Biotechnology peers
Gross Margin
93.03%vs Biotechnology peers
Profit Margin
-7.66%vs Biotechnology peers
Operating Margin
-11.45%vs Biotechnology peers
Return on Assets (TTM)
-5.49%vs Biotechnology peers
Return on Equity (TTM)
-13.68%vs Biotechnology peers
Revenue (TTM)
606.33MUSDvs all stocks (USD)
Revenue per Share (TTM)
14.12USDUpdated Sep 28, 2026Quarterly Revenue Growth
69.40%vs Biotechnology peers
Gross Profit (TTM)
501.26MUSDvs all stocks (USD)
EBITDA (TTM)
-46.20MUSDvs all stocks (USD)
Net Income (TTM)
-46.48MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
69.41%vs Biotechnology peers
Operating Cash Flow (TTM)
74.16MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
67.47MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
451.36MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
30.68MUSDFY2025 · Dec 31, 2025Gross Profit
420.68MUSDFY2025 · Dec 31, 2025Operating Income
-70.97MUSDvs all stocks (USD)
Pre-tax Income
-64.36MUSDFY2025 · Dec 31, 2025Income Tax Expense
2.06MUSDFY2025 · Dec 31, 2025Net Income
-66.42MUSDFY2025 · Dec 31, 2025EBIT
-56.02MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-54.20MUSDFY2025 · Dec 31, 2025Research & Development
64.32MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
427.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
15.75MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
8.34MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.59USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.59USDFY2025 · Dec 31, 2025Basic Shares Outstanding
41.78MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
41.78MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-66.42MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-10.64MUSDFY2025 · Dec 31, 2025Free Cash Flow
-20.50MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
186.20MUSDFY2025 · Dec 31, 2025Interest Paid
8.34MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-66.42MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.82MUSDFY2025 · Dec 31, 2025Stock-based Compensation
41.72MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.27MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-39.05MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.91MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
43.11MUSDFY2025 · Dec 31, 2025Capital Expenditures
-9.86MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-394.06MUSDFY2025 · Dec 31, 2025Sale of Investments
361.80MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-42.12MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
134.77MUSDFY2025 · Dec 31, 2025Shares Outstanding
43.27MSharesUpdated Sep 28, 2026Float Shares
32.74MSharesUpdated Sep 28, 2026Shares Short
6.13MSharesUpdated Sep 28, 2026Short Ratio
7.90daysvs all stocks
Short % of Shares Outstanding
13.50%vs all stocks
% Held by Insiders
2.69%vs all stocks
% Held by Institutions
99.89%vs all stocks
Total Cash (MRQ)
449.69MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
10.25USDUpdated Sep 28, 2026Total Debt (MRQ)
88.81MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2561xvs Biotechnology peers
Current Ratio (MRQ)
3.20xvs Biotechnology peers
Book Value per Share (MRQ)
8.01USDUpdated Sep 28, 2026Total Assets
562.16MUSDvs all stocks (USD)
Total Current Assets
522.78MUSDFY2025 · Dec 31, 2025Total Liabilities
218.73MUSDFY2025 · Dec 31, 2025Total Non-current Assets
39.38MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
83.04MUSDFY2025 · Dec 31, 2025Total Current Liabilities
135.69MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
183.64MUSDFY2025 · Dec 31, 2025Other Short-term Investments
233.63MUSDFY2025 · Dec 31, 2025Accounts Receivable
85.06MUSDFY2025 · Dec 31, 2025Inventory
4.37MUSDFY2025 · Dec 31, 2025Accounts Payable
16.39MUSDFY2025 · Dec 31, 2025Other Current Liabilities
22.18MUSDFY2025 · Dec 31, 2025Long-term Debt
72.44MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
10.60MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-426.63MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
343.43MUSDvs all stocks (USD)
52-Week Low
53.89USDUpdated Sep 28, 202652-Week High
91.53USDUpdated Sep 28, 202652-Week Change
29.77%vs all stocks
Beta
0.5410xvs all stocks
50-Day MA
70.24USDUpdated Sep 28, 2026200-Day MA
68.69USDUpdated Sep 28, 2026Avg 10-Day Volume
615.56KSharesUpdated Sep 28, 2026Avg 30-Day Volume
718.91KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.07USDUpdated Sep 28, 2026Other Income / Expense
-202.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.93Profit Margin: -0.08
Financial Health
Altman Z-Score 9.95: safe zoneNotable
Altman Z-Score: 9.95
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $3.54B, above the global median of $1.2BNotable
Market cap (USD): 3,541,662,864Global Median: 1,201,862,193
Revenue is $606.33M, above the global median of $558.46MNotable
Revenue (USD): 606,331,008Global Median: 558,459,881.051
Levered free cash flow is $67.47M, above the global median of $18.92MNotable
Levered free cash flow (USD): 67,467,872Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Ideaya Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pegbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xenon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Acadia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Organon & Co.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ambu A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Livzon Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Irhythm Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Laboratorios Farmacéuticos Rovi SA
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Yamaichi Electronics Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Ningbo Deye Technology Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated